Nuveen LLC Boosts Stock Position in Elevance Health, Inc. $ELV

Nuveen LLC boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 1.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,975,317 shares of the company’s stock after acquiring an additional 27,199 shares during the quarter. Nuveen LLC’s holdings in Elevance Health were worth $692,447,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Xponance LLC lifted its position in Elevance Health by 4.4% in the 4th quarter. Xponance LLC now owns 36,318 shares of the company’s stock valued at $12,731,000 after acquiring an additional 1,533 shares in the last quarter. Keel Point LLC lifted its position in Elevance Health by 10.0% in the 4th quarter. Keel Point LLC now owns 972 shares of the company’s stock valued at $341,000 after acquiring an additional 88 shares in the last quarter. SmartHarvest Portfolios LLC bought a new position in Elevance Health in the 4th quarter valued at approximately $334,000. Atlanta Consulting Group Advisors LLC bought a new position in Elevance Health in the 4th quarter valued at approximately $326,000. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its position in Elevance Health by 1.6% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 505,539 shares of the company’s stock valued at $177,217,000 after acquiring an additional 8,199 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on ELV. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Mizuho upped their price objective on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research report on Monday. Truist Financial upped their price objective on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Jefferies Financial Group lowered their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, UBS Group increased their price target on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $416.11.

Elevance Health Price Performance

NYSE ELV opened at $399.64 on Friday. The business’s fifty day moving average price is $364.53 and its 200-day moving average price is $344.44. The stock has a market capitalization of $86.79 billion, a price-to-earnings ratio of 17.00, a PEG ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $426.98.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts predict that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.